Molecular targets for breast cancer therapy and prevention

被引：228
作者：
Bange, J [1 ]
Zwick, E [1 ]
Ullrich, A [1 ]
机构：
[1] Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany
来源：
NATURE MEDICINE | 2001年 / 7卷 / 05期
关键词：
D O I：
10.1038/87872
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The recent completion of the human genome sequence has raised great hopes in the discovery of new breast cancer therapies based on newly-discovered genes linked to breast cancer development and progression. Here we describe breast cancer therapies that have emerged from gene-base scientific efforts over the past 20 years and that are now approved for clinical testing or treatment.
引用
收藏
页码：548 / 552
页数：5
相关论文
共 66 条
  • [1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    Alizadeh, AA
    Eisen, MB
    Davis, RE
    Ma, C
    Lossos, IS
    Rosenwald, A
    Boldrick, JG
    Sabet, H
    Tran, T
    Yu, X
    Powell, JI
    Yang, LM
    Marti, GE
    Moore, T
    Hudson, J
    Lu, LS
    Lewis, DB
    Tibshirani, R
    Sherlock, G
    Chan, WC
    Greiner, TC
    Weisenburger, DD
    Armitage, JO
    Warnke, R
    Levy, R
    Wilson, W
    Grever, MR
    Byrd, JC
    Botstein, D
    Brown, PO
    Staudt, LM
    [J]. NATURE, 2000, 403 (6769) : 503 - 511
  • [2] OVEREXPRESSION OF HER-2 NEU AND ITS RELATIONSHIP WITH OTHER PROGNOSTIC FACTORS CHANGE DURING THE PROGRESSION OF INSITU TO INVASIVE BREAST-CANCER
    ALLRED, DC
    CLARK, GM
    MOLINA, R
    TANDON, AK
    SCHNITT, SJ
    GILCHRIST, KW
    OSBORNE, CK
    TORMEY, DC
    MCGUIRE, WL
    [J]. HUMAN PATHOLOGY, 1992, 23 (09) : 974 - 979
  • [3] EXPRESSION OF RAS P21, P53 AND C-ERBB-2 IN ADVANCED BREAST-CANCER AND RESPONSE TO FIRST LINE HORMONAL-THERAPY
    ARCHER, SG
    ELIOPOULOS, A
    SPANDIDOS, D
    BARNES, D
    ELLIS, IO
    BLAMEY, RW
    NICHOLSON, RI
    ROBERTSON, JFR
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (05) : 1259 - 1266
  • [4] Clinical trials of Herceptin® (trastuzumab)
    Baselga, J
    [J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 : S18 - S24
  • [5] ONCOGENE AMPLIFICATION AND PROGNOSIS IN BREAST-CANCER - RELATIONSHIP WITH SYSTEMIC TREATMENT
    BERNS, EMJJ
    FOEKENS, JA
    VANSTAVEREN, IL
    VANPUTTEN, WLJ
    DEKONING, HYWCM
    PORTENGEN, H
    KLIJN, JGM
    [J]. GENE, 1995, 159 (01) : 11 - 18
  • [6] Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
    Boehm, T
    Folkman, J
    Browder, T
    OReilly, MS
    [J]. NATURE, 1997, 390 (6658) : 404 - 407
  • [7] ERBB2 AMPLIFICATION IS ASSOCIATED WITH TAMOXIFEN RESISTANCE IN STEROID-RECEPTOR POSITIVE BREAST-CANCER
    BORG, A
    BALDETORP, B
    FERNO, M
    KILLANDER, D
    OLSSON, H
    RYDEN, S
    SIGURDSSON, H
    [J]. CANCER LETTERS, 1994, 81 (02) : 137 - 144
  • [8] CARTER SK, 1972, CANCER-AM CANCER SOC, V30, P1543, DOI 10.1002/1097-0142(197212)30:6<1543::AID-CNCR2820300621>3.0.CO
  • [9] 2-V
  • [10] Ciardiello F, 2000, CLIN CANCER RES, V6, P2053
1234567